Trial Profile
A Phase II Trial of R435(Bevacizumab) in stage IVB, persistent or recurrent carcinoma of the cervix
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 02 Nov 2016 Status changed from active, no longer recruiting to completed.
- 08 Jun 2016 New trial record